{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:48:30Z","timestamp":1794473310640,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014042","name":"DOD Peer Reviewed Cancer Research Program","doi-asserted-by":"publisher","award":["W81XWH2210784"],"award-info":[{"award-number":["W81XWH2210784"]}],"id":[{"id":"10.13039\/100014042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["R01CA204373"],"award-info":[{"award-number":["R01CA204373"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-025-01227-5","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:57:36Z","timestamp":1744005456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PET imaging of hepatocellular carcinoma with [124I]IV-14"],"prefix":"10.1186","volume":"15","author":[{"given":"Wei","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Sergeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kresak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Destiny","family":"Lusinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Berridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Wojtylak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiubai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest Ricky","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogen","family":"Saunthararajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2429-9911","authenticated-orcid":false,"given":"Zhenghong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"12","key":"1227_CR1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","volume":"3","author":"T Akinyemiju","year":"2017","unstructured":"Global Burden of Disease Liver Cancer C, Akinyemiju T, Abera S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683\u201391.","journal-title":"JAMA Oncol"},{"issue":"15","key":"1227_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450\u201362.","journal-title":"N Engl J Med"},{"issue":"2","key":"1227_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00261-011-9794-x","volume":"37","author":"C Ayuso","year":"2012","unstructured":"Ayuso C, Rimola J, Garcia-Criado A. Imaging of HCC. Abdom Imaging. 2012;37(2):215\u201330.","journal-title":"Abdom Imaging"},{"issue":"3","key":"1227_CR4","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M. American association for the study of liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020\u20132.","journal-title":"Hepatology"},{"issue":"9","key":"1227_CR5","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrc882","volume":"2","author":"SS Gambhir","year":"2002","unstructured":"Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2(9):683\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1227_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1227_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.cld.2015.01.004","volume":"19","author":"HN Simpson","year":"2015","unstructured":"Simpson HN, McGuire BM. Screening and detection of hepatocellular carcinoma. Clin Liver Dis. 2015;19(2):295\u2013307.","journal-title":"Clin Liver Dis"},{"key":"1227_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/JHC.S390939","volume":"10","author":"O Sergeeva","year":"2023","unstructured":"Sergeeva O, Zhang Y, Gao S, et al. PET imaging of hepatocellular carcinoma using ZD2-((68)Ga-NOTA). J Hepatocell Carcinoma. 2023;10:291\u2013301.","journal-title":"J Hepatocell Carcinoma"},{"issue":"4","key":"1227_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.gastha.2022.04.014","volume":"1","author":"O Sergeeva","year":"2022","unstructured":"Sergeeva O, Zhang Y, Julian W, et al. Imaging of tumor-associated vascular prostate-specific membrane antigen in woodchuck model of hepatocellular carcinoma. Gastro Hep Adv. 2022;1(4):631\u20139.","journal-title":"Gastro Hep Adv"},{"issue":"10","key":"1227_CR10","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2967\/jnumed.124.268147","volume":"65","author":"AJ Poot","year":"2024","unstructured":"Poot AJ, Lapa C, Weber WA, et al. [(68)Ga]Ga-RAYZ-8009: a Glypican-3-targeted diagnostic radiopharmaceutical for hepatocellular carcinoma molecular imaging-a first-in-human case series. J Nucl Med. 2024;65(10):1597\u2013603.","journal-title":"J Nucl Med"},{"issue":"7","key":"1227_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrclinonc.2015.75","volume":"12","author":"W Grootjans","year":"2015","unstructured":"Grootjans W, de Geus-Oei LF, Troost EG, Visser EP, Oyen WJ, Bussink J. PET in the management of locally advanced and metastatic NSCLC. Nat Rev Clin Oncol. 2015;12(7):395\u2013407.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1227_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/BF02985627","volume":"20","author":"AC Civelek","year":"2006","unstructured":"Civelek AC, Piotrowski B, Osman MM, et al. Cutaneous metastatic lung cancer detected with 18F-FDG PET. Ann Nucl Med. 2006;20(2):147\u20139.","journal-title":"Ann Nucl Med"},{"issue":"2","key":"1227_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3892\/or.2013.2886","volume":"31","author":"K Izuishi","year":"2014","unstructured":"Izuishi K, Yamamoto Y, Mori H, et al. Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer. Oncol Rep. 2014;31(2):701\u20136.","journal-title":"Oncol Rep"},{"issue":"10","key":"1227_CR14","first-page":"1811","volume":"36","author":"T Torizuka","year":"1995","unstructured":"Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36(10):1811\u20137.","journal-title":"J Nucl Med"},{"issue":"2","key":"1227_CR15","doi-asserted-by":"publisher","first-page":"W260","DOI":"10.2214\/AJR.11.6995","volume":"197","author":"A Sacks","year":"2011","unstructured":"Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET\/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol. 2011;197(2):W260\u20135.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"1227_CR16","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S0168-8278(00)80248-2","volume":"32","author":"MA Khan","year":"2000","unstructured":"Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32(5):792\u20137.","journal-title":"J Hepatol"},{"issue":"2","key":"1227_CR17","first-page":"213","volume":"44","author":"CL Ho","year":"2003","unstructured":"Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44(2):213\u201321.","journal-title":"J Nucl Med"},{"issue":"5","key":"1227_CR18","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3390\/cancers11050688","volume":"11","author":"E Villa","year":"2019","unstructured":"Villa E, Ali ES, Sahu U, Ben-Sahra I. Cancer cells tune the signaling pathways to empower de novo synthesis of nucleotides. Cancers (Basel). 2019;11(5):688.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"1227_CR19","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/3337","volume":"4","author":"AF Shields","year":"1998","unstructured":"Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4(11):1334\u20136.","journal-title":"Nat Med"},{"issue":"15","key":"1227_CR20","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1073\/pnas.1524212113","volume":"113","author":"W Kim","year":"2016","unstructured":"Kim W, Le TM, Wei L, et al. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity. Proc Natl Acad Sci U S A. 2016;113(15):4027\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"1227_CR21","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.2967\/jnumed.109.065896","volume":"50","author":"F Eckel","year":"2009","unstructured":"Eckel F, Herrmann K, Schmidt S, et al. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. J Nucl Med. 2009;50(9):1441\u20137.","journal-title":"J Nucl Med"},{"issue":"3","key":"1227_CR22","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2967\/jnumed.116.182394","volume":"58","author":"MJ Barrio","year":"2017","unstructured":"Barrio MJ, Spick C, Radu CG, et al. Human biodistribution and radiation dosimetry of (18)F-Clofarabine, a PET probe targeting the deoxyribonucleoside salvage pathway. J Nucl Med. 2017;58(3):374\u20138.","journal-title":"J Nucl Med"},{"issue":"5","key":"1227_CR23","first-page":"212","volume":"10","author":"O Sergeeva","year":"2020","unstructured":"Sergeeva O, Zhang Y, Kenyon J, et al. Liver background uptake of [(18)F]FLT in PET imaging. Am J Nucl Med Mol Imaging. 2020;10(5):212\u201325.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"11","key":"1227_CR24","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3390\/cancers11111748","volume":"11","author":"O Sergeeva","year":"2019","unstructured":"Sergeeva O, Kepe V, Zhang Y, et al. [(18)F] clofarabine for PET imaging of hepatocellular carcinoma. Cancers (Basel). 2019;11(11):1748.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"1227_CR25","first-page":"1504","volume":"1862","author":"AB van Kuilenburg","year":"2016","unstructured":"van Kuilenburg AB, Meinsma R. The pivotal role of uridine-cytidine kinases in pyrimidine metabolism and activation of cytotoxic nucleoside analogues in neuroblastoma. Biochem Biophys Acta. 2016;1862(9):1504\u201312.","journal-title":"Biochem Biophys Acta"},{"issue":"5","key":"1227_CR26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S0026-895X(24)12578-3","volume":"59","author":"AR Van Rompay","year":"2001","unstructured":"Van Rompay AR, Norda A, Linden K, Johansson M, Karlsson A. Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol. 2001;59(5):1181\u20136.","journal-title":"Mol Pharmacol"},{"issue":"10\u201312","key":"1227_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/15257770.2015.1124998","volume":"35","author":"R Meinsma","year":"2016","unstructured":"Meinsma R, van Kuilenburg AB. Purification, activity, and expression levels of two uridine-cytidine kinase isoforms in neuroblastoma cell lines. Nucleosides Nucleotides Nucleic Acids. 2016;35(10\u201312):613\u20138.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"1227_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.830362","volume":"12","author":"X Zhong","year":"2022","unstructured":"Zhong X, Yu X, Chang H. Exploration of a novel prognostic nomogram and diagnostic biomarkers based on the activity variations of hallmark gene sets in hepatocellular carcinoma. Front Oncol. 2022;12: 830362.","journal-title":"Front Oncol"},{"issue":"9","key":"1227_CR29","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1111\/cas.14125","volume":"110","author":"Y Wu","year":"2019","unstructured":"Wu Y, Jamal M, Xie T, et al. Uridine-cytidine kinase 2 (UCK2): a potential diagnostic and prognostic biomarker for lung cancer. Cancer Sci. 2019;110(9):2734\u201347.","journal-title":"Cancer Sci"},{"issue":"4","key":"1227_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/mc.22954","volume":"58","author":"S Huang","year":"2019","unstructured":"Huang S, Li J, Tam NL, et al. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness. Mol Carcinog. 2019;58(4):603\u201315.","journal-title":"Mol Carcinog"},{"issue":"11","key":"1227_CR31","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2967\/jnumed.109.065623","volume":"50","author":"BD Zlatopolskiy","year":"2009","unstructured":"Zlatopolskiy BD, Morgenroth A, Kunkel FH, et al. Synthesis and biologic study of IV-14, a new ribonucleoside radiotracer for tumor visualization. J Nucl Med. 2009;50(11):1895\u2013903.","journal-title":"J Nucl Med"},{"issue":"25","key":"1227_CR32","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1021\/jm960537g","volume":"39","author":"H Hattori","year":"1996","unstructured":"Hattori H, Tanaka M, Fukushima M, Sasaki T, Matsuda A. Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)-cytosine, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity. J Med Chem. 1996;39(25):5005\u201311.","journal-title":"J Med Chem"},{"issue":"4","key":"1227_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1349-7006.2002.tb01276.x","volume":"93","author":"Y Shimamoto","year":"2002","unstructured":"Shimamoto Y, Kazuno H, Murakami Y, et al. Cellular and biochemical mechanisms of the resistance of human cancer cells to a new anticancer ribo-nucleoside, TAS-106. Jpn J Cancer Res. 2002;93(4):445\u201352.","journal-title":"Jpn J Cancer Res"},{"issue":"2","key":"1227_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s002800050952","volume":"44","author":"S Takatori","year":"1999","unstructured":"Takatori S, Kanda H, Takenaka K, et al. Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil. Cancer Chemother Pharmacol. 1999;44(2):97\u2013104.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1227_CR35","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0304-3835(97)00188-2","volume":"116","author":"S Tabata","year":"1997","unstructured":"Tabata S, Tanaka M, Endo Y, Obata T, Matsuda A, Sasaki T. Anti-tumor mechanisms of 3\u2032-ethynyluridine and 3\u2032-ethynylcytidine as RNA synthesis inhibitors: development and characterization of 3\u2032-ethynyluridine-resistant cells. Cancer Lett. 1997;116(2):225\u201331.","journal-title":"Cancer Lett"},{"issue":"3","key":"1227_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11307-007-0092-5","volume":"9","author":"N Salem","year":"2007","unstructured":"Salem N, MacLennan GT, Kuang Y, et al. Quantitative evaluation of 2-deoxy-2[F-18]fluoro-D-glucose-positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histological correlation. Mol Imaging Biol. 2007;9(3):135\u201343.","journal-title":"Mol Imaging Biol"},{"issue":"2","key":"1227_CR37","first-page":"144","volume":"53","author":"N Salem","year":"2009","unstructured":"Salem N, Kuang Y, Wang F, Maclennan GT, Lee Z. PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F] fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline. Q J Nucl Med Mol Imaging. 2009;53(2):144\u201356.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"3","key":"1227_CR38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/hep.1840090321","volume":"9","author":"BE Korba","year":"1989","unstructured":"Korba BE, Wells FV, Baldwin B, et al. Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology. 1989;9(3):461\u201370.","journal-title":"Hepatology"},{"issue":"12","key":"1227_CR39","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"3","key":"1227_CR40","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/hep.25730","volume":"56","author":"SP Fletcher","year":"2012","unstructured":"Fletcher SP, Chin DJ, Ji Y, et al. Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology. 2012;56(3):820\u201330.","journal-title":"Hepatology"},{"issue":"5","key":"1227_CR41","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.str.2004.02.038","volume":"12","author":"NN Suzuki","year":"2004","unstructured":"Suzuki NN, Koizumi K, Fukushima M, Matsuda A, Inagaki F. Structural basis for the specificity, catalysis, and regulation of human uridine-cytidine kinase. Structure. 2004;12(5):751\u201364.","journal-title":"Structure"},{"issue":"7768","key":"1227_CR42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41586-019-1373-2","volume":"572","author":"N Aizarani","year":"2019","unstructured":"Aizarani N, Saviano A, Sagar N, et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature. 2019;572(7768):199\u2013204.","journal-title":"Nature"},{"key":"1227_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1755-1536-3-3","volume":"3","author":"A Sokolovic","year":"2010","unstructured":"Sokolovic A, Sokolovic M, Boers W, Elferink RP, Bosma PJ. Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells. Fibrogenesis Tissue Repair. 2010;3:3.","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"1","key":"1227_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4254\/wjh.v11.i1.1","volume":"11","author":"A Desai","year":"2019","unstructured":"Desai A, Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review. World J Hepatol. 2019;11(1):1\u201318.","journal-title":"World J Hepatol"},{"issue":"1","key":"1227_CR45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2967\/jnumed.110.080366","volume":"52","author":"Y Kuang","year":"2011","unstructured":"Kuang Y, Salem N, Tian H, et al. Imaging lipid synthesis in hepatocellular carcinoma with [methyl-11c]choline: correlation with in vivo metabolic studies. J Nucl Med. 2011;52(1):98\u2013106.","journal-title":"J Nucl Med"},{"issue":"6","key":"1227_CR46","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1021\/mp1001922","volume":"7","author":"Y Kuang","year":"2010","unstructured":"Kuang Y, Salem N, Corn DJ, et al. Transport and metabolism of radiolabeled choline in hepatocellular carcinoma. Mol Pharm. 2010;7(6):2077\u201392.","journal-title":"Mol Pharm"},{"issue":"7","key":"1227_CR47","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s00259-011-1743-y","volume":"38","author":"JA Kolthammer","year":"2011","unstructured":"Kolthammer JA, Corn DJ, Tenley N, et al. PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline. Eur J Nucl Med Mol Imaging. 2011;38(7):1248\u201356.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1227_CR48","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11307-010-0308-y","volume":"13","author":"N Salem","year":"2011","unstructured":"Salem N, Kuang Y, Corn D, et al. [(Methyl)1-(11)c]-acetate metabolism in hepatocellular carcinoma. Mol Imaging Biol. 2011;13(1):140\u201351.","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"1227_CR49","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11302-020-09711-4","volume":"16","author":"H Wang","year":"2020","unstructured":"Wang H, Wang X, Xu L, Zhang J, Cao H. High expression levels of pyrimidine metabolic rate-limiting enzymes are adverse prognostic factors in lung adenocarcinoma: a study based on the cancer genome atlas and gene expression omnibus datasets. Purinergic Signal. 2020;16(3):347\u201366.","journal-title":"Purinergic Signal"},{"key":"1227_CR50","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.2147\/CMAR.S182859","volume":"10","author":"Q Zhou","year":"2018","unstructured":"Zhou Q, Jiang H, Zhang J, et al. Uridine-cytidine kinase 2 promotes metastasis of hepatocellular carcinoma cells via the Stat3 pathway. Cancer Manag Res. 2018;10:6339\u201355.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"1227_CR51","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/iub.1941","volume":"71","author":"S Yu","year":"2019","unstructured":"Yu S, Li X, Guo X, Zhang H, Qin R, Wang M. UCK2 upregulation might serve as an indicator of unfavorable prognosis of hepatocellular carcinoma. IUBMB Life. 2019;71(1):105\u201312.","journal-title":"IUBMB Life"},{"issue":"11","key":"1227_CR52","doi-asserted-by":"publisher","first-page":"383","DOI":"10.62347\/QSII4050","volume":"17","author":"DG Dominguez-Lazcano","year":"2024","unstructured":"Dominguez-Lazcano DG, Simon-Lara I, Morales-Romero J, et al. Alpha-fetoprotein, glypican-3, and kininogen-1 as biomarkers for the diagnosis of hepatocellular carcinoma. Int J Clin Exp Pathol. 2024;17(11):383\u201395.","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"1227_CR53","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00726-017-2517-z","volume":"50","author":"Z Wang","year":"2018","unstructured":"Wang Z, Han YJ, Huang S, et al. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET. Amino Acids. 2018;50(2):309\u201320.","journal-title":"Amino Acids"},{"issue":"1","key":"1227_CR54","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11307-019-01356-z","volume":"22","author":"Y Li","year":"2020","unstructured":"Li Y, Zhang J, Gu J, et al. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma. Mol Imaging Biol. 2020;22(1):134\u201343.","journal-title":"Mol Imaging Biol"},{"key":"1227_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.679336","volume":"11","author":"J Yan","year":"2021","unstructured":"Yan J, Yu X, Chen X, et al. Identification of a Glypican-3 Binding peptide from a phage-displayed peptide library for PET imaging of hepatocellular carcinoma. Front Oncol. 2021;11: 679336.","journal-title":"Front Oncol"},{"issue":"3","key":"1227_CR56","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/hep.21531","volume":"45","author":"L Di Tommaso","year":"2007","unstructured":"Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007;45(3):725\u201334.","journal-title":"Hepatology"},{"issue":"15","key":"1227_CR57","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","volume":"26","author":"D Shi","year":"2020","unstructured":"Shi D, Shi Y, Kaseb AO, et al. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for advanced hepatocellular carcinoma: results of Phase I Trials. Clin Cancer Res. 2020;26(15):3979\u201389.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1227_CR58","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/molecules26010004","volume":"26","author":"MM Bell","year":"2021","unstructured":"Bell MM, Gutsche NT, King AP, et al. Glypican-3-Targeted Alpha particle therapy for hepatocellular carcinoma. Molecules. 2021;26(1):4.","journal-title":"Molecules"},{"issue":"4","key":"1227_CR59","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2967\/jnumed.123.266766","volume":"65","author":"F Lin","year":"2024","unstructured":"Lin F, Clift R, Ehara T, et al. Peptide binder to Glypican-3 as a theranostic agent for hepatocellular carcinoma. J Nucl Med. 2024;65(4):586\u201392.","journal-title":"J Nucl Med"},{"issue":"7","key":"1227_CR60","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.21873\/anticanres.13508","volume":"39","author":"B El Hassouni","year":"2019","unstructured":"El Hassouni B, Infante J, Mantini G, et al. Uridine cytidine kinase 2 as a potential biomarker for treatment with RX-3117 in pancreatic cancer. Anticancer Res. 2019;39(7):3609\u201314.","journal-title":"Anticancer Res"},{"issue":"12","key":"1227_CR61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41389-020-00287-7","volume":"9","author":"J Cai","year":"2020","unstructured":"Cai J, Sun X, Guo H, et al. Non-metabolic role of UCK2 links EGFR-AKT pathway activation to metastasis enhancement in hepatocellular carcinoma. Oncogenesis. 2020;9(12):103.","journal-title":"Oncogenesis"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01227-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T06:34:39Z","timestamp":1744007679000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-025-01227-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1227"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01227-5","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants performed by any of the authors. All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed with IACUC approval for Protocol #2014-0085.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}